Hospital
Ahs Hospital Corp.
Ahs Hospital Corp. was paid $36.23M by Medicaid between Jan 2018 and Dec 2024, across 274 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoAHS HOSPITAL CORP.
POMPTON PLAINS, NJ 07444
POMPTON PLAINS, NJ 07444
33aNPI1811994809assigned 07/05/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$36.23M
24GClaims793,702
24DCodes billed274
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#43 of 93
Median peer was paid$30.60M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WALTER, JOSEPH controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81,138 | $4.69M | |
| 2019 | 85,412 | $4.63M | |
| 2020 | 78,343 | $3.81M | |
| 2021 | 110,647 | $5.69M | |
| 2022 | 156,429 | $6.10M | |
| 2023 | 168,435 | $6.21M | |
| 2024incomplete | 113,298 | $5.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 22,495 | 20,856 | $5.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 16,261 | 14,491 | $5.08M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 11,614 | 10,391 | $3.81M |
| G0378 | Hospital observation service, per hour | 6.5% | 10,454 | 4,104 | $2.34M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 7,680 | 7,334 | $1.40M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 4,346 | 4,053 | $1.38M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.1% | 40,562 | 9,760 | $1.11M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.8% | 4,246 | 1,705 | $1.02M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 2,117 | 1,932 | $772K |
| OP710 | 2.0% | 5,224 | 4,211 | $714K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 8,608 | 7,651 | $622K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.7% | 22,137 | 6,217 | $607K |
262 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 5,802 | $585K |
| OP270 | 1.6% | 11,423 | $565K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.5% | 6,656 | $552K |
| OP250 | 1.4% | 77,293 | $497K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 2,015 | $493K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 7,308 | $481K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 9,860 | $432K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.1% | 374 | $397K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,194 | $340K |
| OP272 | <1% | 9,415 | $303K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,755 | $250K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,157 | $236K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,470 | $216K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,103 | $214K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 8,032 | $207K |
| 80053 | Comprehensive metabolic panel | <1% | 25,713 | $206K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,918 | $202K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,624 | $202K |
| 96376 | <1% | 5,304 | $198K | |
| 93017 | <1% | 662 | $197K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 7,829 | $195K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,426 | $184K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,608 | $175K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,907 | $159K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,406 | $149K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,239 | $145K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,473 | $140K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,506 | $132K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,259 | $118K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,830 | $109K |
| 97161 | <1% | 2,590 | $93K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,646 | $93K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 178 | $92K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,708 | $90K |
| 76641 | <1% | 704 | $89K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,058 | $84K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,447 | $80K |
| 84484 | <1% | 10,371 | $77K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,429 | $75K |
| 93970 | <1% | 441 | $73K | |
| 93971 | <1% | 668 | $70K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 385 | $64K |
| 97162 | <1% | 2,256 | $62K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,644 | $59K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,821 | $58K |
| 72100 | <1% | 1,214 | $51K | |
| 96367 | <1% | 1,055 | $50K | |
| 71250 | <1% | 379 | $49K | |
| 83880 | <1% | 3,550 | $47K | |
| 73630 | <1% | 1,359 | $45K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 273 | $44K |
| 73560 | <1% | 1,794 | $43K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 54 | $42K |
| 73610 | <1% | 1,263 | $41K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 83 | $41K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,027 | $40K |
| 85610 | <1% | 12,931 | $40K | |
| 85730 | <1% | 11,666 | $40K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 123 | $40K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 980 | $39K |
| 82962 | <1% | 10,504 | $39K | |
| 81001 | <1% | 14,051 | $39K | |
| 83735 | <1% | 8,257 | $39K | |
| 76642 | <1% | 505 | $38K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,231 | $38K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,930 | $37K |
| 73130 | <1% | 1,096 | $37K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 186 | $36K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,140 | $36K |
| 73030 | <1% | 1,137 | $36K | |
| 76536 | <1% | 361 | $35K | |
| 83690 | <1% | 8,430 | $35K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 655 | $33K |
| 77080 | <1% | 360 | $32K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 354 | $30K |
| 77065 | Tomosynthesis, mammo | <1% | 418 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,954 | $27K |
| 86850 | <1% | 2,909 | $27K | |
| 87486 | <1% | 1,597 | $26K | |
| 83605 | <1% | 3,399 | $26K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 162 | $26K |
| 87040 | <1% | 2,718 | $26K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 973 | $26K |
| 73110 | <1% | 626 | $22K | |
| 64450 | <1% | 28 | $22K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,130 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,602 | $21K |
| 72131 | <1% | 219 | $20K | |
| 86900 | <1% | 3,257 | $20K | |
| 87581 | <1% | 1,600 | $20K | |
| 81025 | <1% | 8,326 | $19K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,686 | $19K |
| 87631 | <1% | 536 | $19K | |
| 74018 | <1% | 699 | $19K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,629 | $19K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,756 | $17K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 177 | $17K |
| 86901 | <1% | 3,273 | $16K | |
| 82150 | <1% | 3,017 | $16K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 202 | $16K |
| 82550 | <1% | 4,061 | $16K | |
| C9399 | Unclassified drugs or biologicals | <1% | 266 | $16K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 31 | $15K |
| 0002A | <1% | 491 | $15K | |
| OP258 | <1% | 12,834 | $15K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,999 | $13K |
| 97116 | <1% | 1,301 | $13K | |
| 84702 | <1% | 1,640 | $13K | |
| 85027 | <1% | 3,194 | $12K | |
| 0001A | <1% | 472 | $12K | |
| OP370 | <1% | 278 | $12K | |
| 90715 | <1% | 666 | $12K | |
| 84145 | <1% | 1,848 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 531 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,084 | $11K |
| 77066 | Tomosynthesis, mammo | <1% | 96 | $10K |
| 99241 | <1% | 426 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 592 | $10K |
| J3490 | Unclassified drugs | <1% | 12,167 | $10K |
| 87077 | <1% | 1,682 | $9K | |
| 84100 | <1% | 2,652 | $9K | |
| 87186 | <1% | 1,457 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,318 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,678 | $8K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 321 | $8K |
| 76770 | <1% | 74 | $8K | |
| 80061 | Lipid panel | <1% | 1,343 | $8K |
| 85378 | <1% | 2,032 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,554 | $8K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 491 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,381 | $8K |
| 73502 | <1% | 194 | $7K | |
| 81003 | <1% | 1,844 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 860 | $6K |
| 12001 | <1% | 170 | $6K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 131 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,111 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,802 | $6K |
| 11045 | <1% | 20 | $5K | |
| 70486 | <1% | 48 | $5K | |
| 0012A | <1% | 172 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,505 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,215 | $4K |
| 0011A | <1% | 168 | $4K | |
| 0004A | <1% | 114 | $4K | |
| 87070 | <1% | 630 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,093 | $4K |
| 94760 | <1% | 226 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 850 | $4K |
| 72040 | <1% | 98 | $3K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 14 | $3K |
| 86140 | <1% | 2,004 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,775 | $3K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 12,295 | $3K |
| 29125 | <1% | 99 | $3K | |
| 93226 | <1% | 16 | $3K | |
| 73590 | <1% | 71 | $3K | |
| 85652 | <1% | 1,954 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 873 | $3K |
| 93976 | <1% | 13 | $3K | |
| 73080 | <1% | 75 | $3K | |
| 82077 | <1% | 628 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 128 | $2K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,393 | $2K |
| 93880 | <1% | 12 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 128 | $2K |
| 90686 | <1% | 1,039 | $2K | |
| 93225 | <1% | 16 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,466 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 68 | $2K |
| 01480 | <1% | 15 | $2K | |
| C1769 | Guide wire | <1% | 110 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 34 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,606 | $2K |
| 88304 | <1% | 130 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 19 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,664 | $2K |
| 97166 | <1% | 75 | $2K | |
| 84703 | <1% | 600 | $1K | |
| 90670 | <1% | 251 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 128 | $1K |
| 82607 | <1% | 249 | $1K | |
| 87205 | <1% | 583 | $1K | |
| 80143 | <1% | 295 | $1K | |
| 76813 | <1% | 13 | $1K | |
| 76870 | <1% | 13 | $1K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 53 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 42 | $1K |
| 90698 | <1% | 561 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,265 | $1K |
| 97165 | <1% | 27 | $1K | |
| 90674 | <1% | 46 | $1K | |
| 80179 | <1% | 246 | $1K | |
| 72070 | <1% | 25 | $964.95 | |
| 82746 | <1% | 224 | $952.13 | |
| 90651 | <1% | 28 | $935.57 | |
| 97750 | <1% | 229 | $918.84 | |
| 0064A | <1% | 28 | $897.68 | |
| 80320 | <1% | 43 | $844.70 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 517 | $834.91 |
| 82728 | <1% | 118 | $821.87 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 861 | $814.32 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 676 | $808.47 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 340 | $781.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 450 | $759.52 |
| 82553 | <1% | 76 | $703.89 | |
| 90734 | <1% | 55 | $703.74 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $671.10 |
| 29515 | <1% | 29 | $658.58 | |
| 84466 | <1% | 173 | $611.72 | |
| 90714 | <1% | 93 | $566.49 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 222 | $527.57 |
| 87075 | <1% | 75 | $463.59 | |
| 96368 | <1% | 17 | $462.65 | |
| 92523 | <1% | 14 | $460.00 | |
| 99201 | <1% | 13 | $446.32 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 989 | $430.62 |
| 0003A | <1% | 12 | $408.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 40 | $407.41 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 276 | $395.72 |
| 0124A | <1% | 14 | $377.62 | |
| 83540 | <1% | 174 | $364.54 | |
| OP255 | <1% | 102 | $307.33 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 30 | $286.19 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 706 | $283.45 |
| 84550 | <1% | 113 | $272.45 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 386 | $243.48 |
| OP279 | <1% | 40 | $243.36 | |
| 87076 | <1% | 39 | $230.10 | |
| 94664 | <1% | 38 | $230.01 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 847 | $212.51 |
| 00731 | <1% | 12 | $204.24 | |
| 82803 | <1% | 26 | $194.11 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 92 | $173.19 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 216 | $164.16 |
| 87430 | <1% | 47 | $154.86 | |
| 90682 | <1% | 13 | $133.52 | |
| 83615 | <1% | 80 | $128.98 | |
| 90681 | <1% | 86 | $128.45 | |
| 90744 | <1% | 110 | $124.84 | |
| 86308 | <1% | 56 | $118.42 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 57 | $111.87 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 117 | $107.45 |
| 87081 | <1% | 35 | $95.34 | |
| 90671 | <1% | 233 | $87.35 | |
| 80076 | <1% | 30 | $81.82 | |
| 90474 | <1% | 60 | $76.34 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 51 | $64.02 |
| 85379 | <1% | 33 | $54.50 | |
| 90656 | <1% | 91 | $47.99 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 29 | $47.76 |
| 84439 | <1% | 14 | $37.47 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 43 | $33.93 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 39 | $29.68 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 52 | $26.72 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 14 | $18.31 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $17.45 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $13.53 |
| 90633 | <1% | 27 | $10.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 21 | $5.77 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 53 | $5.00 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 16 | $4.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALTER, JOSEPH (SVP, CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Ahs Hospital Corp. | Morristown, NJ | $155.87M |
| Ahs Hospital Corp. | Summit, NJ | $125.20M |
| Ahs Hospital Corp | Newton, NJ | $33.62M |
| Ahs Hospital Corp | Hackettstown, NJ | $16.26M |
| Ahs Hospital Corp. | Morristown, NJ | $5.20M |
| Ahs Hospital Corp. | Newton, NJ | $4.82M |
| Ahs Hospital Corp. | Newton, NJ | $1.26M |
| Ahs Hospital Corp | Morristown, NJ | $171K |
| Ahs Hospital Corp. | Morristown, NJ | $1K |
| Ahs Hospital Corp. | Morristown, NJ | $1K |
| Ahs Hospital Corp. | Morristown, NJ | $708.57 |
| Ahs Hospital Corp | Morristown, NJ | $149.55 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.